Clinical Trials Logo

Biliary Tract Cancers clinical trials

View clinical trials related to Biliary Tract Cancers.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT05924880 Active, not recruiting - Clinical trials for Biliary Tract Cancers

A Phase 3b, Open-label, Multi-center Study on Durvalumab in Combination With Gemcitabine-based Chemotherapy as 1L Treatment for the Chinese Patients With Unresectable Biliary Tract Cancers (BTC)

TopDouble
Start date: July 21, 2023
Phase: Phase 3
Study type: Interventional

This is a Phase IIIb, open-label, single arm, multicentre study to assess the safety and efficacy of durvalumab in combination with investigator's choice of 3 different gemcitabine-based chemotherapy regimens in participants with aBTC with a WHO/ECOG PS of 0 to 2 at enrolment.

NCT ID: NCT03797326 Active, not recruiting - Colorectal Cancer Clinical Trials

Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005)

Start date: February 12, 2019
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine the safety and efficacy of combination therapy with pembrolizumab (MK-3475) and lenvatinib (E7080/MK-7902) in participants with triple negative breast cancer (TNBC), ovarian cancer, gastric cancer, colorectal cancer (CRC), glioblastoma (GBM), biliary tract cancers (BTC), or pancreatic cancer.